Cure Pharmaceutical (OTC:CURR) announced today that it received confirmation of a patent for its Curefilm Blue platform.\ The U.S. Patent Office (USPTO) provided notification to Cure that U.S. Patent No. 11,179,331 (the ’331 patent) is set to issue on November 23, 2021. The ‘331 patent (“Oral Soluble Film Containing Sildenafil Citrate”) covers Curefilm blue. Oxnard, […]
Cure Pharmaceutical
Cure Pharmaceutical touts data from Curefilm Blue trial for erectile dysfunction
Cure Pharmaceutical announced today that it observed positive results from a trial for its Curefilm Blue platform. Oxnard, Calif.-based Cure touted the results of its initial pharmacokinetics (PK)/bioequivalence studies ahead of the advancement of its clinical program in pursuit of FDA approval, according to a news release. The company did not reveal the specific data, […]
Cure Pharmaceutical launches antiviral, anti-seizure development programs
Drug delivery technology developer Cure Pharmaceutical (OTC:CURR) announced today that it launched two new clinical development programs. Oxnard, Calif.-based Cure’s first new launch is an antiviral clinical development program for loading a known active pharmaceutical ingredient (API) onto its Curefilm patented drug delivery platform that optimizes the absorption and metabolism of therapeutic devices, according to […]
